295 related articles for article (PubMed ID: 22204764)
21. Proteasome inhibitors in cancer therapy.
Manasanch EE; Orlowski RZ
Nat Rev Clin Oncol; 2017 Jul; 14(7):417-433. PubMed ID: 28117417
[TBL] [Abstract][Full Text] [Related]
22. The resistance mechanisms of proteasome inhibitor bortezomib.
Lü S; Wang J
Biomark Res; 2013 Mar; 1(1):13. PubMed ID: 24252210
[TBL] [Abstract][Full Text] [Related]
23. Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies.
Wolska-Washer A; Smolewski P
Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954440
[TBL] [Abstract][Full Text] [Related]
24. Proteasome inhibition and its therapeutic potential in multiple myeloma.
Chari A; Mazumder A; Jagannath S
Biologics; 2010 Sep; 4():273-87. PubMed ID: 21116326
[TBL] [Abstract][Full Text] [Related]
25. Proteasome inhibitors in cancer therapy.
Crawford LJ; Walker B; Irvine AE
J Cell Commun Signal; 2011 Jun; 5(2):101-10. PubMed ID: 21484190
[TBL] [Abstract][Full Text] [Related]
26. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Dou QP; Zonder JA
Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
[TBL] [Abstract][Full Text] [Related]
27. Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.
Zhao Y; Zhang K; Li G; Zhang X; Shi D
PLoS One; 2015; 10(5):e0127334. PubMed ID: 25973846
[TBL] [Abstract][Full Text] [Related]
28. Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis.
Bustany S; Cahu J; Descamps G; Pellat-Deceunynck C; Sola B
J Hematol Oncol; 2015 Apr; 8():40. PubMed ID: 25898974
[TBL] [Abstract][Full Text] [Related]
29. Overcoming bortezomib resistance in multiple myeloma.
Murray MY; Auger MJ; Bowles KM
Biochem Soc Trans; 2014 Aug; 42(4):804-8. PubMed ID: 25109961
[TBL] [Abstract][Full Text] [Related]
30. From bortezomib to other inhibitors of the proteasome and beyond.
Buac D; Shen M; Schmitt S; Kona FR; Deshmukh R; Zhang Z; Neslund-Dudas C; Mitra B; Dou QP
Curr Pharm Des; 2013; 19(22):4025-38. PubMed ID: 23181572
[TBL] [Abstract][Full Text] [Related]
31. DeepAEG: a model for predicting cancer drug response based on data enhancement and edge-collaborative update strategies.
Lao C; Zheng P; Chen H; Liu Q; An F; Li Z
BMC Bioinformatics; 2024 Mar; 25(1):105. PubMed ID: 38461284
[TBL] [Abstract][Full Text] [Related]
32. Inferring circRNA-drug sensitivity associations via dual hierarchical attention networks and multiple kernel fusion.
Lu S; Liang Y; Li L; Liao S; Zou Y; Yang C; Ouyang D
BMC Genomics; 2023 Dec; 24(1):796. PubMed ID: 38129810
[TBL] [Abstract][Full Text] [Related]
33. MNCLCDA: predicting circRNA-drug sensitivity associations by using mixed neighbourhood information and contrastive learning.
Li G; Zeng F; Luo J; Liang C; Xiao Q
BMC Med Inform Decis Mak; 2023 Dec; 23(1):291. PubMed ID: 38110886
[TBL] [Abstract][Full Text] [Related]
34. Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway.
Ludwig MP; Galbraith MD; Eduthan NP; Hill AA; Clay MR; Tellez CM; Wilky BA; Elias A; Espinosa JM; Sullivan KD
Cancer Res; 2023 Aug; 83(15):2543-2556. PubMed ID: 37205634
[TBL] [Abstract][Full Text] [Related]
35. Unfolded protein response and angiogenesis in malignancies.
Izadpanah A; Willingham K; Chandrasekar B; Alt EU; Izadpanah R
Biochim Biophys Acta Rev Cancer; 2023 Mar; 1878(2):188839. PubMed ID: 36414127
[TBL] [Abstract][Full Text] [Related]
36. Two novel piperidones induce apoptosis and antiproliferative effects on human prostate and lymphoma cancer cell lines.
Swain RM; Contreras L; Varela-Ramirez A; Hossain M; Das U; Valenzuela CA; Penichet ML; Dimmock JR; Aguilera RJ
Invest New Drugs; 2022 Oct; 40(5):905-921. PubMed ID: 35793039
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for renal impairment in patients with hematological cancer receiving antineoplastic treatment.
Travassos PNC; de Barros Silva PG; Freitas MO; Braga MDM; Duarte FB; de Oliveira Maia JK; Pitombeira H; de Sousa JH; Alves APNN
Support Care Cancer; 2022 Sep; 30(9):7271-7280. PubMed ID: 35596773
[TBL] [Abstract][Full Text] [Related]
38. Establishment and characterization of a novel patient-derived Ewing sarcoma cell line, NCC-ES2-C1.
Yoshimatsu Y; Noguchi R; Sin Y; Tsuchiya R; Ono T; Akiyama T; Nakagawa R; Kamio S; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
Hum Cell; 2022 Jul; 35(4):1262-1269. PubMed ID: 35441357
[TBL] [Abstract][Full Text] [Related]
39. Three novel piperidones exhibit tumor-selective cytotoxicity on leukemia cells via protein degradation and stress-mediated mechanisms.
Contreras L; Medina S; Schiaffino Bustamante AY; Borrego EA; Valenzuela CA; Das U; Karki SS; Dimmock JR; Aguilera RJ
Pharmacol Rep; 2022 Feb; 74(1):159-174. PubMed ID: 34448104
[TBL] [Abstract][Full Text] [Related]
40. CHIP/STUB1 Ubiquitin Ligase Functions as a Negative Regulator of ErbB2 by Promoting Its Early Post-Biosynthesis Degradation.
Luan H; Bailey TA; Clubb RJ; Mohapatra BC; Bhat AM; Chakraborty S; Islam N; Mushtaq I; Storck MD; Raja SM; Band V; Band H
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
